If you want to know who really controls Sinopharm Group Co. Ltd. (HKG:1099), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
While institutions who own 22% came under pressure after market cap dropped to HK$53b last week,private companies took the most losses.
Let's take a closer look to see what the different types of shareholders can tell us about Sinopharm Group.
Check out our latest analysis for Sinopharm Group
SEHK:1099 Ownership Breakdown August 22nd 2022
What Does The Institutional Ownership Tell Us About Sinopharm Group?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Sinopharm Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Sinopharm Group's earnings history below. Of course, the future is what really matters.
SEHK:1099 Earnings and Revenue Growth August 22nd 2022
Sinopharm Group is not owned by hedge funds. China National Pharmaceutical Group Corporation is currently the company's largest shareholder with 57% of shares outstanding. With such a huge stake in the ownership, we infer that they have significant control of the future of the company. Meanwhile, the second and third largest shareholders, hold 4.7% and 2.6%, of the shares outstanding, respectively.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Sinopharm Group
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our data suggests that insiders own under 1% of Sinopharm Group Co. Ltd. in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around HK$2.7m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.
General Public Ownership
The general public, who are usually individual investors, hold a 21% stake in Sinopharm Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
Our data indicates that Private Companies hold 57%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Sinopharm Group has 1 warning sign we think you should be aware of.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道誰真正控制了國藥控股股份有限公司(HKG:1099),那麼你就得看看它的股票登記簿的構成。我們可以看到,私營公司以57%的所有權擁有該公司的最大份額。也就是説,如果股價上漲,該集團將受益最大(如果股價下跌,該集團將損失最大)。
雖然在上週市值跌至530億港元后,持有22%股份的機構面臨壓力,但私營公司損失最大。
讓我們仔細看看不同類型的股東能告訴我們關於國藥控股的什麼。
看看我們對國藥控股的最新分析
聯交所:1099擁有權分類2022年8月22日
關於國藥控股,機構所有制告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
國藥控股已經在股票登記處登記了機構。事實上,他們在該公司擁有可觀的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面國藥控股的收入歷史值得一看。當然,未來才是真正重要的。
聯交所:1099盈利及收入增長2022年8月22日
國藥控股並不為對衝基金所有。中國醫藥集團公司目前是該公司的最大股東,持有57%的流通股。由於擁有如此巨大的股權,我們推斷他們對公司的未來擁有重大控制權。與此同時,第二大和第三大股東分別持有4.7%和2.6%的流通股。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。有很多分析師在追蹤這隻股票,所以他們的預測可能也是值得的。
國藥控股的內部人所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們的數據顯示,內部人士以自己的名義持有國藥控股股份有限公司不到1%的股份。然而,我們確實注意到,內部人士可能通過私人公司或其他公司結構擁有間接利益。它是一家相當大的公司,因此董事會成員有可能在該公司擁有有意義的權益,而不是擁有太多按比例分配的權益。在這種情況下,他們擁有價值約270萬港元的股票(按當前價格計算)。看到董事會成員持有股票是件好事,但可能值得檢查一下這些內部人士是否一直在買入。
一般公有制
通常為個人投資者的普通公眾持有國藥控股21%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私營公司所有權
我們的數據顯示,私營公司持有該公司57%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。以風險為例-國藥控股有1個警告標誌我們認為你應該意識到。
最終未來是最重要的。您可以訪問此免費分析師對該公司的預測報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。